Literature DB >> 7891851

The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons.

Y L Hurd1, Z B Pristupa, M M Herman, H B Niznik, J E Kleinman.   

Abstract

Dysfunction of dopamine neural systems is hypothesized to underlie neuropsychiatric disorders and psychostimulant drug abuse. At least three dopamine systems have been characterized in the brain-nigrostriatal, mesolimbic, and mesocortical. Abnormalities of nigrostriatal dopamine neurons cause motor impairment leading to Parkinson's disease, whereas dysfunction of mesolimbic and mesocortical dopamine neurons are most implicated in psychotic disorders such as schizophrenia and in drug addition. One of the primary neural sites of action of potent antipsychotic agents and psychostimulant drugs of abuse are dopamine receptors and dopamine transporters which, respectively, mediate the induction and termination of dopamine's actions. Very limited information is, however, available about which particular set of dopaminergic cells in the human brain actually express the genes for these dopamine-specific proteins. In this study, we observed that the dopamine transporter and D2 receptor messenger RNAs are differentially expressed within the human mesencephalon: highest expression in ventral subpopulations of the substantia nigra pars compacta neurons with lowest expression in the mesolimbic/mesocortical ventral tegmental area and retrorubral cell groups. These findings suggest that motor- and limbic-related mesencephalic neurons in the human brain differ in the degree of dopamine transporter and D2 receptor gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7891851     DOI: 10.1016/0306-4522(94)90535-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

1.  Dopamine release and uptake dynamics within nonhuman primate striatum in vitro.

Authors:  S J Cragg; C J Hille; S A Greenfield
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.

Authors:  S J Cragg; S A Greenfield
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Identification of an intronic cis-acting element in the human dopamine transporter gene.

Authors:  Ying Zhao; Yanhong Zhou; Nian Xiong; Zhicheng Lin
Journal:  Mol Biol Rep       Date:  2011-12-13       Impact factor: 2.316

4.  Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro.

Authors:  K Z Shen; S W Johnson
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

5.  Dopamine Inhibition Differentially Controls Excitability of Substantia Nigra Dopamine Neuron Subpopulations through T-Type Calcium Channels.

Authors:  Rebekah C Evans; Manhua Zhu; Zayd M Khaliq
Journal:  J Neurosci       Date:  2017-03-06       Impact factor: 6.167

6.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

7.  Dopamine D₂ and acetylcholine α7 nicotinic receptors have subcellular distributions favoring mediation of convergent signaling in the mouse ventral tegmental area.

Authors:  M Garzón; A M Duffy; J Chan; M-K Lynch; K Mackie; V M Pickel
Journal:  Neuroscience       Date:  2013-08-15       Impact factor: 3.590

Review 8.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

Review 9.  Heterogeneity in Dopamine Neuron Synaptic Actions Across the Striatum and Its Relevance for Schizophrenia.

Authors:  Nao Chuhma; Susana Mingote; Abigail Kalmbach; Leora Yetnikoff; Stephen Rayport
Journal:  Biol Psychiatry       Date:  2016-07-12       Impact factor: 13.382

10.  Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.

Authors:  T J Counihan; J B Penney
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.